Cardiff Oncology, Inc. (NASDAQ: CRDF)

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies through the inhibition of PLK1, a validated oncology drug target. The company's primary activity involves the research and development of onvansertib, an oral and highly selective PLK1 inhibitor, designed to be used in combination with standard-of-care therapeutics to treat various solid tumor and hematologic malignancies. Cardiff Oncology leverages tumor genomics and biomarker assays to refine patient selection and assess treatment response in its clinical programs.

Cardiff Oncology generates revenue through the advancement of its drug candidate onvansertib via clinical development milestones, potential future licensing agreements, and possible product sales upon regulatory approval. The company does not currently have commercial products on the market and therefore does not generate revenue from drug sales. Its financial support comes from equity financings, strategic partnerships, and non-dilutive funding sources tied to clinical trial progress and intellectual property development.

The company operates through the following segments: Cardiff Oncology operates in one business segment, using a single measurement of profitability to manage its operations.

• The company's sole business segment encompasses all activities related to the research, development, and clinical testing of onvansertib across multiple cancer indications including RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia.

Cardiff Oncology positions itself as a developer of a highly selective oral PLK1 inhibitor with a differentiated profile compared to prior PLK1 inhibitors that lacked specificity. The company believes onvansertib's potency, selectivity, oral bioavailability, and short half-life offer advantages in safety and tolerability, particularly when combined with standard-of-care agents. Its competitive landscape includes other PLK inhibitors such as volasertib and plogosertib, but Cardiff Oncology asserts that onvansertib is the only oral PLK1 inhibitor in active clinical development delivering highly selective PLK1 inhibition.

The company serves patients with specific oncologic indications who are enrolled in clinical trials conducted at medical centers and research institutions. These include patients with RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, relapsed small cell lung cancer, unresectable locally advanced or metastatic triple negative breast cancer, and chronic myelomonocytic leukemia. Cardiff Oncology collaborates with investigators at institutions such as the University of Kansas Medical Center, University of Maryland Baltimore, Dana Farber Cancer Institute, and others to conduct its investigator-initiated trials.